The use of protein therapeutics over non-protein drugs is expected to increase throughout the forecasted period, which would boost the global market for protein engineering. Therapeutic proteins are used to treat a wide range of illnesses, such as cancer and HIV. Monoclonal antibodies, cytokines, and IFNs are examples of the macromolecular therapeutic proteins. Since they are more efficient and safer than chemical drugs, therapeutic agents derived from proteins and peptides may be employed. There are now about 60 US FDA-approved peptide medications on the market, and during the projected period, this number is anticipated to rise. Over the course of the projected period, it is anticipated that the prevalence of diseases caused by protein deficiencies would rise across the globe. One vital component of a basic diet is protein, yet an estimated one billion people worldwide lack enough of it. Worldwide, the National Institutes of Health (NIH) calculates a 12.2% risk of protein deficiency. Furthermore, according to NIH estimates, demographic shifts will put 1.4 billion individuals, or 15.1% of the world's population, at danger of protein deficiencies by 2050.
According to Coherent Market Insights, The market for Protein Engineering worldwide is expected to reach US$ 5,355.8 Mn in 2028, growing at a CAGR of 15.6% between 2022 and 2028 from an estimated value of US$ 1,936.7 Mn in 2021.
Leading Companies in the Protein Engineering Industry:
1. Thermo Fisher Scientific Inc.
The company was started in 1956 and is located in Waltham, Massachusetts, U.S. The business offers applications, reagents and consumables, and scientific apparatus. Thermo Fisher Scientific stated in January 2021 that it had purchased Groupe Novasep SAS's viral vector maker, Henogen SA, in Belgium. In an all-cash agreement worth US$2.6 billion, the business agreed to acquire Nordic Capital's British diagnostics company, The Binding Site Group, in October 2022.
2. Bio-Rad Laboratories Inc.
The firm was founded in 1952 and is based in California, United States. The business produces and sells analytical instruments, clinical diagnostics, and equipment for use in life science research. Products and systems from Bio-Rad Laboratories are used to separate complicated chemical and biological materials as well as to recognise, examine, and purify their constituent parts. A cooperation between Bio-Rad and Roche was declared in March 2021.
3. Agilent Technologies
The company was established in 1999 and is located in California, United States. Agilent Technologies, Inc. offers fundamental electronic measurement and bio-analytical solutions to the chemical analysis, communications, electronics, and life sciences industries. The business provides semiconductor and board testing, as well as electronic and bioanalytical measurement.
4. PerkinElmer, Inc.
The company was started in 1937 and is based in Waltham, Massachusetts, United States. The company's main areas of focus are translational multi-omics technologies, biomarker identification, imaging, forecasting, screening, detecting and diagnosing, and informatics. PerkinElmer declared that the acquisition of Oxford Immunotec Global PLC had been completed in March 2021. PerkinElmer announced its intention to purchase Horizon Discovery Group in November 2020 for about US$383 million.
5. Bruker Corporation
The company was founded in 1960 and is based in Billerica, Massachusetts, United States. Bruker Corporation creates, produces, and sells customised life science systems based on spectrometry technology frameworks. Inscopix, Inc., a manufacturer of miniature microscopes and miniscopes with its headquarters in Mountain View, was acquired by Bruker, it was revealed in November 2022.
6. Waters Corporation
The company was founded in 1958 and is based in Milford, Massachusetts, United States. High-performance liquid chromatography products and services are available from Waters Corporation. The business sells its goods to a variety of global businesses, including those that deal with chemicals, medicines, and environmental testing. In February 2023, Waters will pay $1.36 billion in cash to buy Wyatt Technology. In May 2023, the acquisition was finalised.
7. Abzena, Ltd.
The business was started in 2014 and is based in San Diego, CA, USA. Abzena Limited offers services for the development of biotherapeutics and antibody drug conjugates (ADCs). The company provides services for finding antibodies, candidate screening, immunology, determining immunogenicity, bioconjugation, and producing biopharmaceuticals.
Definition: Through the creation of intelligent, stimulus-responsive medication delivery systems, protein engineering has the potential to completely alter the metabolic medicine market. The rapidly expanding field of protein treatments will enhance the long-term clinical outcomes of drugs licenced by the Food and Drug Administration (FDA).
